Phase 2RecruitingAge-related condition
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
- Sponsor
- National Cancer Institute (NCI) (NIH)
- Enrollment
- 90 planned
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Placebo Administration; Urolithin A Supplement
- Ages
- adults, older adults
- Registry
- NCT06022822
Full record on ClinicalTrials.gov
From the registry
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tissue oxidative stress (measured by 8-OHdG) compared to placebo.
Primary outcomes
- Percent positive change in 8-OHdG
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered